NASDAQ: MEIP

MEI Pharma, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MEI Pharma, Inc. (NASDAQ: MEIP) resulting from allegations that MEI Pharma may have issued materially misleading business information to the investing public.

If you purchased MEI Pharma securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased MEI Pharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 13, 2022, after market hours, MEI Pharma announced restatements of its financial statements for certain quarters for 2020 and 2021. In part, MEI Pharma stated, “[R]evenue was overstated in some quarters and understated in other quarters in the Company’s financial statements during 2020 and 2021. The Company will therefore restate its previously filed annual and quarterly financial statements for periods from June 30, 2020 forward.”

On this news, MEI Pharma share prices fell $0.0242, or 4.6%, to open at $0.4958 per share on May 16, 2022, damaging investors.

Follow us on:
Company Name: MEI Pharma, Inc.
Stock Symbol: NEIP
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top